Certified by Founder
Lodge
Rampart Bioscience
start up
United States
- Delhi, California
- 25/10/2023
- Series A
- $85,000,000
Rampart Bioscience is evolving a new class of medicines for patients with genetically driven diseases. We integrate capabilities from a variety of key scientific disciplines — including gene delivery, protein sciences and clinical translation — to leap beyond the limitations of current gene therapies.
Powered by our novel non-viral DNA delivery system, we are on a path to achieve higher standards for potency, durability, redosability and safety. Together, we are working to reshape the treatment landscape for people in dire need of better options.
- Industry Biotechnology Research
- Website https://rampartbio.com/
- LinkedIn https://www.linkedin.com/company/rampart-bioscience/about/
Dark Watch | $3,500,000 | (Mar 17, 2026)
Alomana | $4,597,680 | (Mar 17, 2026)
Gangkhar | $4,250,000 | (Mar 17, 2026)
Malama Health | $9,200,000 | (Mar 17, 2026)
Great Sky | $14,000,000 | (Mar 17, 2026)
Understood Care | $5,000,000 | (Mar 17, 2026)
AgZen | $10,000,000 | (Mar 17, 2026)
Certiv | $4,200,000 | (Mar 17, 2026)
Scanner | $22,000,000 | (Mar 17, 2026)
Zero RFI | $13,800,000 | (Mar 17, 2026)
Nadia Care | $12,000,000 | (Mar 17, 2026)
Eileen Inc. | $1,000,000 | (Mar 17, 2026)
Halcyon(US) | $21,000,000 | (Mar 17, 2026)